2. The effects of n‐3 LCPUFA supplementation on all allergies using pooled analysis RR (M‐H, Fixed, 95% CI).

Allergy (IgE mediated or not)	Assessed Age	No of studies	No of participants	n‐3 LCPUFA		Placebo		Effect Estimate RR [95% CI]
				Events	Total	Events	Total
Food allergy	< 12 months	1	117	1	52	10	65	0.13 [0.02, 0.95] ٭
	12‐36 months	4	973	19	499	26	474	0.72 [0.40 to 1.30]
	≥ 36 months	1	706	14	368	9	338	1.43 [0.63 to 3.26]
Eczema	< 12 months	2	203	16	100	20	103	0.76 [0.22 to 2.62]R
	12‐36 months	4	973	118	499	122	474	0.96 [0.69 to 1.33]R
	≥ 36 months	2	1237	122	628	131	609	0.88 [0.68 to 1.13]R
Allergic rhinitis	< 12 months	0	0					NE
	12‐36 months	2	805	10	414	18	391	0.53 [0.25 to 1.12]
	≥ 36 months	2	1169	114	593	109	576	1.03 [0.81 to 1.30]
Asthma	< 12 months	1	83	11	46	7	37	1.26 [0.54 to 2.94]
	12‐36 months	4	955	106	491	105	464	0.93 [0.73 to 1.18]
	≥ 36 months	3	1697	165	856	171	841	0.94 [0.78 to 1.13]
Any allergies	< 12 months	0	0					NE
	12‐36 months	2	823	109	422	117	401	0.89 [0.71 to 1.11]
	≥ 36 months	3	1765	270	891	274	874	0.96 [0.84 to 1.09]

*significant P < 0.05, ٭٭ significant P < 0.005, NE= Not estimable , ^R= Random‐effects estimate